Drug Profile


Alternative Names: STNM-01

Latest Information Update: 09 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Stelic Institute & Co
  • Developer Sameshima Hospital; Stelic Institute & Co
  • Class Anti-inflammatories; Antifibrotics; Antiulcers
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Ulcerative colitis
  • Phase I Crohn's disease

Most Recent Events

  • 09 Nov 2017 Stelic Institute completes a phase I clinical trial for Ulcerative colitis and Crohn's disease (Treatment-experienced) in Japan (Submucosal) (UMIN000020900; 9226074)
  • 13 Jul 2016 Stelic Institute & Co. completes a phase II trial in Ulcerative colitis in Germany (EudraCT2012-004768-23)
  • 08 Feb 2016 Phase I clinical trials in Ulcerative colitis and Crohn's disease (Treatment-experienced) in Japan (Submucosal) (UMIN000020900)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top